Terje Lund
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Terje Lund has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Aase-Brith Jensen
Department of Endocrinology – Section Hormone Laboratory, Oslo University Hospital, Norway
1 shared publicationAud Svindland
Department of Pathology, Oslo University Hospital, Norway
1 shared publicationBente Kilhovd
Department of Endocrinology, Oslo University Hospital, Norway
1 shared publication- Jens Petter Berg
Department of Medical Biochemistry, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
1 shared publication Kristian F Hanssen
Department of Endocrinology, Oslo University Hospital, Norway
1 shared publicationMilaim Pepaj
Department of Endocrinology – Section Hormone Laboratory, Oslo University Hospital, Norway
1 shared publication
Latest Publications
- Open Access
- 15 August 2011
- Published by SAGE Publications in Diabetes & Vascular Disease Research
- Vol. 8 (4) , 284-294
Fibrin(ogen) may be an important target for methylglyoxal-derived AGE modification in elastic arteries of humans
Diabetes is associated with increased risk of cardiovascular disease. Advanced glycation end-products (AGEs) are considered to be a major pathogenic factor for diabetic vascular complications. The levels of AGEs are increased in diabetic patients. We have studied the presence of the major AGE methylglyoxal (MGO)-derived hydroimidazolone in human aorta and carotid arteries, using immunohistochemistry (IHC), western blotting and mass spectrometry. By IHC, MGO-derived modifications were detected mainly associated with cells in intimal thickenings and cells in microvessels in adventitia. In type V lesions MGO-derived AGE was also present, extracellular in the necrotic core and in cells at the border of the core. The highest degree of modification was probably associated with cell nuclei. By western blotting and mass spectrometry fibrin(ogen), the cytoskeleton-associated protein moesin and the nuclear proteins lamin A and C were identified as putative main targets for MGO-derived modification. LC-MS/MS studies of fibrin(ogen) modified in vitro with low concentrations of MGO identified the sites that were most prone to modification. These results indicate that AGE modifications occur preferentially on specific proteins. The modification of these proteins may play a role in vascular dysfunction and development of atherosclerosis in diabetes.
- 15 August 2011
- Published by SAGE Publications in Diabetes & Vascular Disease Research
- Vol. 8 (4) , 284-294
Open AccessFibrin(ogen) may be an important target for methylglyoxal-derived AGE modification in elastic arteries of humans
Diabetes is associated with increased risk of cardiovascular disease. Advanced glycation end-products (AGEs) are considered to be a major pathogenic factor for diabetic vascular complications. The levels of AGEs are increased in diabetic patients. We have studied the presence of the major AGE methylglyoxal (MGO)-derived hydroimidazolone in human aorta and carotid arteries, using immunohistochemistry (IHC), western blotting and mass spectrometry. By IHC, MGO-derived modifications were detected mainly associated with cells in intimal thickenings and cells in microvessels in adventitia. In type V lesions MGO-derived AGE was also present, extracellular in the necrotic core and in cells at the border of the core. The highest degree of modification was probably associated with cell nuclei. By western blotting and mass spectrometry fibrin(ogen), the cytoskeleton-associated protein moesin and the nuclear proteins lamin A and C were identified as putative main targets for MGO-derived modification. LC-MS/MS studies of fibrin(ogen) modified in vitro with low concentrations of MGO identified the sites that were most prone to modification. These results indicate that AGE modifications occur preferentially on specific proteins. The modification of these proteins may play a role in vascular dysfunction and development of atherosclerosis in diabetes.